Comparison · NCT03829969-4cfcbb00
Toripalimab vs Placebo: ORR(Overall Response Rate:BICR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Toripalimab vs Placebo: ORR(Overall Response Rate:BICR). Trial comparisons, record NCT03829969-4cfcbb00. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03829969-4cfcbb00
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.693 | 0.634 | 0.746 | wilson | |
| Risk in group 2 | 0.521 | 0.46 | 0.582 | wilson | |
| Risk difference, group 1 minus group 2 | 0.171 | 0.0869 | 0.252 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.33 | 1.15 | 1.53 | log | |
| Odds ratio, group 1 over group 2 | 2.07 | 1.44 | 2.97 | log | |
| Number needed to treat, for one more participant with the outcome on Toripalimab than on Placebo | 5.84 | 3.97 | 11.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Toripalimab | Toripalimab combine with paclitaxel and cisplatin~Toripalimab: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy | 178 | 257 | OG000 |
| Group 2 | Placebo | Placebo combine with paclitaxel and cisplatin~Toripalimab: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy | 134 | 257 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- ORR(Overall Response Rate:BICR)
- Description
To evaluate the efficacy of JS001 plus chemotherapy compared with placebo plus chemotherapy, as measured by blind independent review committee BIRC and investigator-assessed overall response rate (ORR), daccording to RECIST v1.1; ORR:Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
- Time frame
- Up to 2 approximately years
- Population
Source ClinicalTrials.gov
Trial
- Title
- Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
- NCT number
- NCT03829969
- Phases
- PHASE3
- Conditions
- Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
- Interventions
- Toripalimab
- Lead sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Results first posted
- 2024-05-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03829969?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03829969-4cfcbb00